Hospira Issues A Voluntary Nationwide Recall Of Symbiq Infusion Systems Due To Inaccurate Response Of The Touch Screen To User Selection/Input

["U.S. Food & Drug Administration (FDA)" <fda@xxxxxxxxxxxxxxxxxxxxxxx>]

Title: Hospira Issues A Voluntary Nationwide Recall Of Symbiq Infusion Systems Due To Inaccurate Response Of The Touch Screen To User Selection/Input

You are subscribed to Recalls, Market Withdrawals and Safety Alerts for U.S. Food & Drug Administration (FDA).

This information has recently been updated and is now available.

 

Hospira Issues A Voluntary Nationwide Recall Of Symbiq Infusion Systems Due To Inaccurate Response Of The Touch Screen To User Selection/Input

10/29/2012 03:57 PM EDT

Hospira, Inc. (NYSE: HSP), announced today it is initiating a voluntary nationwide Class I recall of Symbiq™ infusion systems (list number 16026 Symbiq™ One-Channel Infuser and list number 16027 Symbiq™ Two-Channel Infuser, all serial numbers). This action is due to infusion pump LCD touch screens that may not respond to user selection, resulting in users possibly experiencing a delayed response and/or the screen registering a different value from the value selected by the user.

. For detailed information pertaining to this Recalls, Market Withdrawals and Safety Alerts message, please click the link at the beginning of this bulletin.

---

Manage your FDA Subscriptions:

• Update your preferences or unsubscribe
• Questions about this service? support@xxxxxxxxxxxxxxx
• Other inquiries? webmail@xxxxxxxxxx

---

This email was sent to list-fda@xxxxxxxxxxx using GovDelivery, on behalf of: U.S. Food & Drug Administration (FDA) · 10903 New Hampshire Ave · Silver Spring, MD 20993 · 800-439-1420